Biointaxis

Biointaxis is an academic biotech spin-off from the Health Sciences Research Institute Germans Trias i Pujol (IGTP) in Badalona, Barcelona. The company specializes in developing life-changing treatments for rare genetic diseases, with a particular focus on Friedreich ataxia. Biointaxis creates significant value at the early stages of product development, including research and development (R&D), pre-clinical proof of concept, and regulatory and clinical trials (Phase I/II). The company’s core product is a gene therapy designed to re-establish the function of a defective protein in Friedreich ataxia patients. Biointaxis operates in the biotech and pharmaceutical markets, primarily serving patients with rare genetic disorders. The business model is centered around developing and commercializing gene therapy products, generating revenue through partnerships, licensing agreements, and eventual product sales. The management team includes experienced professionals with extensive backgrounds in finance, biotech, and pharmaceutical industries, ensuring robust strategic and operational guidance.

Keywords: Gene therapy, Friedreich ataxia, rare genetic diseases, biotech, pharmaceutical, R&D, clinical trials, protein function, academic spin-off, IGTP.